Brief: BiomX Announces Discontinuation Of Phase 2b Bx004 Trial Following Internal Review
08/12/2025 12:34
Dec 8 (Reuters) - Biomx Inc PHGE.A: BIOMX ANNOUNCES DISCONTINUATION OF PHASE 2B BX004 TRIAL FOLLOWING INTERNAL REVIEW BIOMX INC - PLANS COST-CUTTING MEASURES INCLUDING WORKFORCE REDUCTION BIOMX INC - DECISION FOLLOWS SAFETY REVIEW BY INDEPENDENT DMC BIOMX INC - SEES POTENTIAL IN BX011 FOR S. AUREUS INFECTIONS Source text: ID:nGNX8KfLKK Further company coverage: PHGE.A ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biomx
See all newsBrief: Biomx Inc - Buys 100% Of Zorronet From Water Io - SEC Filing
Brief: BiomX Obtains Option To Acquire Control Of Israeli Laser-Radar Counter-Drone System
Brief: Biomx Adds Former Mossad Deputy To Advisory Board
Brief: Biomx Inc - Jonathan Solomon Resigns As CEO And Board Member Effective March 4, 2026 - SEC Filing
Brief: BiomX Says Unaware of Any Undisclosed Developments Amid Unusual Stock Trading